Share

April 18, 2017; 88 (16 Supplement) April 26, 2017

Efficacy Results from the Phase 2b SYNERGY Study: Treatment of Disabling Multiple Sclerosis with the Anti-LINGO-1 Monoclonal Antibody Opicinumab (S33.004)

Michelle Mellion, Keith R. Edwards, Raymond Hupperts, Jelena Drulović, Xavier Montalban, Hans-Peter Hartung, Bruno Brochet, Peter A. Calabresi, Richard Rudick, Adama Ibrahim, Yiwei Zhang, Lei Xu, Diego Cadavid
First published April 17, 2017,
Citation
Permissions

Make Comment

See Comments

Downloads
0

Share

Article Information

vol. 88 no. 16 Supplement S33.004
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published April 17, 2017.
Copyright & Usage: 
© 2017

Author Disclosures

    1. Michelle Mellion1,
    2. Keith R. Edwards2,
    3. Raymond Hupperts3,
    4. Jelena Drulović4,
    5. Xavier Montalban5,
    6. Hans-Peter Hartung6,
    7. Bruno Brochet7,
    8. Peter A. Calabresi8,
    9. Richard Rudick1,
    10. Adama Ibrahim1,
    11. Yiwei Zhang1,
    12. Lei Xu1 and
    13. Diego Cadavid9
    14. on behalf of the SYNERGY investigators
  1. Michelle Mellion1,
  2. Keith R. Edwards2,
  3. Raymond Hupperts3,
  4. Jelena Drulović4,
  5. Xavier Montalban5,
  6. Hans-Peter Hartung6,
  7. Bruno Brochet7,
  8. Peter A. Calabresi8,
  9. Richard Rudick1,
  10. Adama Ibrahim1,
  11. Yiwei Zhang1,
  12. Lei Xu1 and
  13. Diego Cadavid9
  1. 1Biogen Cambridge MA United States
  2. 2MS Center of Northeastern NY Latham NY United States
  3. 3Orbis Medisch Centrum, Maastricht University Medical Center Sittard Netherlands
  4. 4Clinic of Neurology, CCS, Faculty of Medicine, University of Belgrade Belgrade Serbia
  5. 5Vall d’Hebron University Hospital Barcelona Spain
  6. 6Department of Neurology, Heinrich-Heine University Dusseldorf Germany
  7. 7Bordeaux Hospital University Centre and University of Bordeaux Bordeaux France
  8. 8The Johns Hopkins Multiple Sclerosis Center Baltimore MD United States
  9. 9Fulcrum Therapeutics Cambridge MA United States

Article usage

Article usage: April 2017 to February 2023

AbstractFullPdfSource
Apr 20178500Highwire
May 201718100Highwire
Jun 20174300Highwire
Jul 20175200Highwire
Aug 20174900Highwire
Sep 20175100Highwire
Oct 20177000Highwire
Nov 201711000Highwire
Dec 20175000Highwire
Jan 20186200Highwire
Feb 20184700Highwire
Mar 20184600Highwire
Apr 20184900Highwire
May 20185000Highwire
Jun 20187200Highwire
Jul 20184100Highwire
Aug 20183100Highwire
Sep 20184400Highwire
Oct 20187100Highwire
Nov 20186700Highwire
Dec 20184500Highwire
Jan 20194800Highwire
Feb 20198300Highwire
Mar 20197700Highwire
Apr 20197500Highwire
May 20197400Highwire
Jun 201910200Highwire
Jul 20197000Highwire
Aug 20193500Highwire
Sep 20193000Highwire
Oct 20194900Highwire
Nov 20192700Highwire
Dec 20192500Highwire
Jan 20201900Highwire
Feb 20202100Highwire
Mar 20202400Highwire
Apr 20203300Highwire
May 20203400Highwire
Jun 20201400Highwire
Jul 20202200Highwire
Aug 2020800Highwire
Sep 20201900Highwire
Oct 20203800Highwire
Nov 20201800Highwire
Dec 20201800Highwire
Jan 20212200Highwire
Feb 20211100Highwire
Mar 20211600Highwire
Apr 20212400Highwire
May 20211200Highwire
Jun 2021600Highwire
Jul 20212000Highwire
Aug 20211000Highwire
Sep 20211300Highwire
Oct 20211700Highwire
Nov 20211000Highwire
Dec 2021600Highwire
Jan 2022400Highwire
Feb 2022900Highwire
Mar 2022900Highwire
Apr 2022500Highwire
May 20221200Highwire
Jun 20221500Highwire
Jul 20221600Highwire
Aug 2022800Highwire
Sep 20221300Highwire
Oct 20221600Highwire
Nov 2022800Highwire
Dec 2022700Highwire
Jan 20231500Highwire
Feb 2023600Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Alert Me